The FLCCC Alliance has officially rebranded as the Independent Medical Alliance (IMA), marking a significant shift in its mission to reshape healthcare in the U.S. Originally established in March 2020, FLCCC gained recognition for its science-backed COVID-19 treatment protocols. As its scope widened to address chronic health issues, informed consent, and healthcare policy, the organization recognized the need for a new identity to better reflect its evolving goals.
“The change to Independent Medical Alliance signifies our unwavering commitment to restoring the doctor-patient relationship and prioritizing patient autonomy in medical decision-making,” said Dr. Joseph Varon, IMA President and Chief Medical Officer. “This is about looking forward—to creating a healthcare system built on trust, integrity, and the principles of informed consent. The future of medicine starts here.”
The timing of this rebrand arrives at a critical moment in the national conversation about healthcare reform. IMA has been a consistent voice in challenging the influence of pharmaceutical companies and government agencies, especially during the COVID-19 pandemic when it promoted early, cost-effective treatments like ivermectin. Now, with the appointment of Robert F. Kennedy Jr. as nominee for the U.S. Department of Health and Human Services, IMA sees an opportunity to further elevate its calls for systemic change.
Dr. Paul Marik, IMA Chief Scientific Officer and Co-founder, shared: “We began as a small group of doctors united to save lives during a crisis. Today, we are a global movement advocating for healthcare reform. Our new name embodies this expanded vision and our commitment to revolutionizing healthcare by ensuring transparency, accountability, and true patient care.”
As the Independent Medical Alliance, the organization will continue to focus on advocating for patient rights, providing evidence-based resources, and fostering a healthcare system grounded in trust, transparency, and patient choice.